Feedback plc Stock
Price
Target price
?
?
37.350%
0.0155
37.350%
-
09:31 / Stuttgart Stock Exchange
WKN: A3DWGX / Name: Feedback / Stock / Holding Companies / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Feedback plc Stock
Feedback plc dominated the market today, gaining €0.016 (37.350%).
Pros and Cons of Feedback plc in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Feedback plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Feedback plc | 37.350% | 25.275% | -12.308% | -63.694% | -43.000% | -95.289% | -92.875% |
| Allerthal-werke-Ag | 0.000% | 0.000% | 1.626% | 35.135% | 15.741% | 4.167% | -3.101% |
| Cfc Industriebeteiligungen | -14.900% | -11.304% | 3.659% | -44.262% | 30.769% | -59.843% | -37.037% |
| Blockmate Ventures Inc. | -15.090% | 13.248% | 52.299% | -64.667% | -47.000% | -83.121% | -87.844% |
News
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type
Tethys Investment Alliance Releases Intelligenter Hightech-Roboter V5 Annual Report, Focusing on System Usage and Feedback-Driven Adjustments
Tethys Investment Alliance has released the annual report for Intelligenter Hightech-Roboter V5, providing a structured overview of the AI system's practical usage over the past year. Founder
